GRAIL, INC. SECURITIES FRAUD NOTICE: Berger Montague Informs GRAIL, Inc. (GRAL) Investors of a Securities Fraud Lawsuit

National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) ("GRAIL" or the "Company") on behalf of investors who purchased or acquired GRAIL common stock during the period from May 13, 2025 through February 19, 2026 (the "Class Period").

Investor Deadline: Investors who purchased or acquired GRAIL common stock during the Class Period may, no later than August 4, 2026, seek to be appointed as a lead plaintiff representative of the class.

Headquartered in Menlo Park, Calif., GRAIL is a life sciences company that develops multi-cancer early detection tests. The Company's lead product, the Galleri test, uses a blood-based genomic analysis to screen for dozens of cancers simultaneously.

According to the suit, while Defendants publicly championed the NHS-Galleri trial and maintained an optimistic narrative around the Galleri platform, they concealed that the trial's design and follow-up duration were materially inadequate to demonstrate the study's primary endpoint.

On February 19, 2026, GRAIL announced that the NHS-Galleri Trial had failed to achieve a statistically significant reduction in late-stage cancers. The Company attributed the shortfall in part to the trial needing a longer follow-up period to yield valid comparisons.

GRAIL's stock plummeted approximately 50.55% on the next trading day, falling from a close of $101.53 per share on February 19, 2026 to a close of $50.21 per share on February 20, 2026.